Genfit SA reports €39.2 million revenue for first nine months of 2025
Genfit SA reported €39.2 million in revenue for the first nine months of 2025, down from €59.7 million in the same period in 2024. The revenue was primarily from a Licensing and Collaboration Agreement with Ipsen. The company had €119.0 million in cash and cash equivalents as of September 30, 2025. Genfit expects its cash position to cover expenses beyond 2028. Key developments include R&D efforts in liver failure and a Phase 1 study of G1090N2. This summary is based on AI-generated content by Public Technologies.
Genfit SA reported cash and cash equivalents of €119.0 million as of September 30, 2025, up from €107.5 million on June 30, 2025, and €81.8 million at the end of 2024. Revenue for the first nine months of 2025 was €39.2 million, compared to €59.7 million for the same period in 2024. Revenue was mainly driven by the Licensing and Collaboration Agreement with Ipsen, including €12.6 million in royalty revenue from worldwide sales of Iqirvo (elafibranor) and a €26.5 million milestone payment following pricing and reimbursement approval in three major European markets. Genfit stated its cash position is expected to fund operating expenses and capital expenditures beyond the end of 2028, based on current assumptions and anticipated revenues. Key business developments include ongoing R&D efforts focused on acute on-chronic liver failure and continued progress in the pipeline, with a Phase 1 study of G1090N2 underway and safety data expected by year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001140028-en) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
